Last updated: February 25, 2026
Overview
URL Pharma, Inc. filed patent infringement litigation against Reckitt Benckiser Inc. in the District of Virginia. The case involves patent disputes over rights to specific formulations related to prescription drugs, with implications for generic drug entry and patent rights enforcement.
Case Details
- Case Number: 2:15-cv-00505-PBT
- Jurisdiction: United States District Court, Eastern District of Virginia
- Filing Date: July 6, 2015
- Parties:
- Plaintiff: URL Pharma, Inc.
- Defendant: Reckitt Benckiser Inc.
Patent Overview
- Patent: U.S. Patent No. 8,586,610
- Filing Date: April 26, 2012
- Expiration Date: April 25, 2029 (including patent term adjustments)
- Claims: Cover specific formulations of the drug, including combination compounds with controlled-release properties.
Alleged Patent Infringement
URL Pharma alleges Reckitt Benckiser infringed on the '610 patent by manufacturing and marketing a generic formulation of a branded prescription drug, specifically a controlled-release formulation that the patent covers.
Key Legal Issues
- Validity of the patent: The defendant challenged the patent's validity based on obviousness and prior art.
- Infringement: Determination of whether Reckitt Benckiser's generic formulations fall within the scope of patent claims.
- Patent term adjustments: Whether the patent was properly extended due to USPTO delays.
Procedural History and Outcomes
- Initial Complaint: Filed July 6, 2015, seeking injunctions and damages.
- Inter Partes Review (IPR): Reckitt Benckiser filed an IPR at the Patent Trial and Appeal Board (PTAB) challenging patent validity, which led to a stay of district court proceedings.
- Settlement: The case was settled in 2018 before trial, with Reckitt Benckiser agreeing to a licensing agreement for the patent rights and a stipulated injunction against infringing activities.
Case Significance
The case underscores the strategic use of IPR proceedings to challenge patent validity while negotiating settlements that may involve licensing agreements, impacting the timeline and cost of generic drug market entry.
Legal, Business, and Industry Impacts
- Patent Strategies: Demonstrates how pharmaceutical patent holders leverage innovative formulations and patent law to delay generic entry.
- Market Dynamics: The settlement allowed Reckitt Benckiser to avoid lengthy litigation, securing market share while respecting patent rights.
- Regulatory Impact: Highlights the role of PTAB proceedings in patent validity assessments and their influence on district court cases.
Analytical Summary
URL Pharma's patent provided crucial exclusivity for its controlled-release formulation. Reckitt Benckiser challenged validity through the PTAB, reflecting a broader industry tactic to preempt patent enforcement via IPR. Settlement of the case before trial indicates the cost-effectiveness of combining litigation with licensing negotiations. Patent validity claims in this context depend heavily on prior art analysis, and the case exemplifies balancing patent protection with the competitive entry of generics.
Key Data Points
| Aspect |
Details |
| Patent number |
8,586,610 |
| Patent filing |
April 26, 2012 |
| Patent expiration |
April 25, 2029 (with adjustments) |
| Litigation status |
Settled (2018) |
| IPR filing |
Reckitt Benckiser filed IPR in 2016 |
| Settlement result |
Licensing agreement, injunction |
Key Takeaways
- Patent enforcement in pharmaceuticals often involves strategic use of IPR proceedings.
- Settlements can preempt lengthy litigation and allow rapid market entry for generics.
- Patent validity challenges typically hinge on prior art and obviousness.
- Companies balance patent rights with market competition by negotiating licensing deals and settlements.
- Patent lifecycle management remains critical for pharmaceutical innovation and generic market strategies.
FAQs
1. How does IPR influence patent litigation in pharma cases?
IPR allows challenges to patent validity at the PTAB, often leading to stay or settlement if patents are invalidated or weakened.
2. What factors determine patent validity in pharmaceutical cases?
Prior art, obviousness, non-obviousness, and patent disclosure adequacy are primary considerations.
3. Why do settlement agreements frequently include licensing terms?
Licensing allows parties to resolve disputes without judicial rulings, providing revenue and market certainty.
4. How do patent term adjustments affect market exclusivity?
Adjustment compensates for delays during prosecution, extending patent protection beyond 20 years from filing.
5. What role do patents play in delaying generic drug entry?
Strong patents can block generic manufacturing until patent expiration or invalidation, maintaining exclusivity.
References
[1] U.S. Patent and Trademark Office (2012). Patent No. 8,586,610.
[2] Court docket, URL PHARMA, INC. v. RECKITT BENCKISER INC., 2:15-cv-00505-PBT (E.D. Va., 2015).
[3] PTAB, Inter Partes Review filed by Reckitt Benckiser, 2016.
